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Objective: To examine the natural history of acute alcoholic hepatitis (AH) and identify predictors of
mortality for AH using data from a prospective multicenter observational study.
Participants and Methods: We analyzed data from 164 patients with AH and 131 heavy-drinking
controls with no liver disease. Participants underwent clinical/laboratory assessment at baseline and 6
and 12 months after enrollment. Multivariable analyses were conducted to identify variables associated
with mortality and examine the association between coffee drinking and risk of AH.
Results: Thirty-six patients with AH died during follow-up, with estimated 30-day, 90-day, 180-day, and
1-year survival of 0.91 (95% CI, 0.87-0.96), 0.85 (95% CI, 0.80-0.91), 0.80 (95% CI, 0.74-0.87), and
0.75 (95% CI, 0.68-0.83), respectively. In the multivariable analysis, higher serum bilirubin level (hazard
ratio [HR]¼1.059; 95% CI, 1.022-1.089), lower hemoglobin level (HR¼1.263; 95% CI, 1.012-1.575),
and lower platelet count (HR¼1.006; 95% CI, 1.001-1.012) were independently associated with mortality
in AH. Compared with controls, fewer patients with AH regularly consumed coffee (20% vs 44%;
P<.001), and this association between regular coffee drinking and lower risk of AH persisted after con-
trolling for relevant covariates (odds ratio¼0.26; 95% CI, 0.15-0.46). Time-dependent receiver operating
characteristic curve analysis revealed that Model for End-Stage Liver Disease; Maddrey Discriminant
Function; age, serum bilirubin, international normalized ratio, and serum creatinine; and Child-Pugh
scores all provided similar discrimination performance at 30 days (area under the curve¼0.73-0.77).
Conclusion: Alcoholic hepatitis remains highly fatal, with 1-year mortality of 25%. Regular coffee con-
sumption was associated with lower risk of AH in heavy drinkers.
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the end of this article.E xcessive alcohol consumption is agrowing trend in the United States,with approximately 87% of the general
population older than 18 years reporting some
history of alcohol consumption and approxi-
mately 25% meeting the criteria for heavy
drinking.1-3 Alcoholic hepatitis (AH) is a unique
syndrome in patients with chronic and active
harmful alcohol use. It is associated with poor
prognosis and reported short-term mortality
of 16% to 50% within 1 month of presentation,
depending on initial disease severity.4-8 Based
on the National Inpatient Sample analysis, AHMayo Clin Proc Inn Qual Out n July 2017;1(1):37-48 n http://dx.do
www.mcpiqojournal.org n ª 2017 Mayo Foundation for Medical Ed
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-accounts for 0.7% of all hospital admissions in
the United States, which is higher than that
formyocardial infarction, acute cerebrovascular
disease, or acute pancreatitis.9,10 No recent
studies have prospectively examined the natural
history of AH in the United States. In addition,
the lack of prospective clinical studies makes it
challenging to validate existing risk stratifica-
tion models, such as the Model for End-Stage
Liver Disease (MELD) score; Lille score; age,
serum bilirubin, international normalized ratio,
serum creatinine (ABIC) score; Child-Pugh
(CP) score; or Maddrey Discriminant Functioni.org/10.1016/j.mayocpiqo.2017.04.004
ucation and Research. Published by Elsevier Inc. This is an open access article under
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38(mDF) score, to classify disease severity and
predict survival in patients with AH.11-13
The risk of alcoholic liver disease is related
to the amount and duration of alcohol
use.14,15 However, only a small proportion
of heavy drinkers develop AH, suggesting
the role of host and environmental factors
on the development of AH.2,4,5,16 Recent
genomic studies reported higher variants of
hepatic antiapoptotic genes such as K8/K18
(keratinocytes) in white individuals or the
PNPLA3 gene in the Hispanic population,
which predisposes them to liver injury.17-19
Furthermore, several studies have suggested
the benefit of regular coffee consumption in
preventing liver disease, albeit limited to
epidemiologic or retrospective studies
involving nonalcoholic fatty liver disease and
liver cancer.20-23 There are limited data, either
prospective or retrospective, that evaluate the
relationship between coffee consumption and
AH in heavy drinkers.
The main objectives of this study were to
describe (1) the outcomes of AH in a cohort us-
ing the new diagnostic definition,24 (2) vari-
ables associated with mortality in AH, (3) the
performance of commonly used risk stratifica-
tion models, and (4) the relationship between
coffee consumption and the risk of AH in heavy
drinkers using a multicenter prospective
cohort. The data presented herein provide addi-
tional complementary analyses beyond a recent
and initial publication describing this cohort.25
PARTICIPANTS AND METHODS
This article is concerned with an ongoing pro-
spective,multicenter, observational study of pa-
tients with well-characterized AH (cases) and
heavy drinkers without evidence of liver disease
(controls) conducted by the Translational
Research and Evolving Alcoholic Hepatitis
Treatment (TREAT) Consortium. The TREAT
Consortium, consisting of Indiana University,
Virginia Commonwealth University, and
Mayo Clinic, is funded by the National Institute
on Alcohol Abuse and Alcoholism and its objec-
tives are to conduct clinical research in AH and
develop novel treatments.
Participants
For the most part, cases were enrolled from
inpatient clinical sites associated with the
respective center in the consortium, andMayo Clin Proc Inn Qual Out n July 2017controls were enrolled from 1 or more of the
local alcohol rehabilitation facilities. However,
outpatients from liver clinics were also candi-
dates for inclusion as cases in the study, but
these individuals’ laboratory values were typi-
cally out of the range for inclusion as cases
and, thus, they were unlikely to be enrolled.
Heavy drinkers were defined as having average
daily alcohol consumption greater than 40 g/d
forwomen or greater than 60 g/d formen for the
last 5 years and active drinking within the 6
weeks before study enrollment, amounts
that are believed to be reasonable minimal
thresholds for the development of AH.24
Frequency-matched (for similar alcohol con-
sumption history) heavy drinkers without liver
disease were recruited to the control group.
Absence of liver disease in the control group
was ascertained based on history, physical ex-
amination findings, and normal liver enzyme
levels. The diagnosis of AH was made by the
admitting clinician based on a combination of
appropriate clinical and laboratory data as per
the new consensus definition of AH24,25 criteria
in the presence of heavy drinking for a mini-
mum of 6 months and within 6 weeks before
enrollment. Subsequent testing, including liver
biopsy in some cases, was performed at the
discretion of the managing clinician for patients
in whom the diagnosis was still in question
based on these criteria. Individuals with hepati-
tis B virus, hepatitis C virus, or human immuno-
deficiency virus were eligible for enrollment as
cases to include the full spectrum of patients
seen with AH in practice. Exclusion criteria for
either cases or controls included (1) younger
than 21 years; (2) evidence of other liver dis-
eases, such as autoimmune or drug induced, he-
mochromatosis, or Wilson disease; (3) active
intravenous drug use; or (4) comorbidities
such as chronic obstructive pulmonary disease,
congestive heart failure, or multiorgan failure.
This study was approved by the institutional re-
view boards at the respective institutions, and
all the participants signed an informed consent
form before enrollment. These cohorts were
described in a recent publication by the TREAT
Consortium.24
Detailed data were collected on (1) demo-
graphic factors (age, sex, race and ethnicity,
marital status, highest educational level), vital
signs, anthropometry, medical history, and
concomitant medications; (2) quantity of;1(1):37-48 n http://dx.doi.org/10.1016/j.mayocpiqo.2017.04.004
www.mcpiqojournal.org
ALCOHOLIC HEPATITIScoffee and tea consumed; (3) complications of
portal hypertension (ascites, jaundice, varices,
hepatic encephalopathy, hepatocellular carci-
noma); (4) laboratory values with calculated
mDF, MELD, ABIC, and CP scores; and (5)
hepatitis B virus, hepatitis C virus, or human
immunodeficiency virus status. Both cases
and controls had follow-up visits 6 and 12
months after enrollment.
Statistical Analyses
Baseline Differences and Logistic Regres-
sion. First, descriptive statistics were used to
describe selected baseline characteristics for
cases and controls. c2 and t tests were used
to test univariate differences in proportions/
means by group for categorical and contin-
uous variables, respectively. Subsequently, lo-
gistic regression was performed to examine
the relationship between selected baseline
characteristics (body mass index [BMI; calcu-
lated as the weight in kilograms divided by
the height in meters squared]; age; sex; regular
coffee consumption [4 times a week for 5
years]; regular tea consumption [4 times a
week for 5 years], measured separately for
black and green tea26; educational level
measured as low, medium, and high; and
marital status) and the presence of AH, with
risk estimates reported as odds ratios (ORs).
Race was not considered for multivariable
analyses due to a very small percentage of
nonwhite participants in the study. All the
variables were screened for entry into the final
model using a cutoff value of P<.20 in uni-
variate models. The Akaike Information Cri-
terion (AIC)27 was subsequently used to
examine relative model fit for all possible
models built using main effects of variables
identified in the first stage. The model with the
minimum AIC was selected as the best model.
Variables Associated With Mortality in
AH. A Kaplan-Meier estimate of survival in
patients with AH was constructed, with CIs as
dotted lines. The Kaplan-Meier estimate for
controls was not calculated because only 1
death (due to drug overdose) was observed.
Next, Cox proportional hazards19 modeling
was used to examine the relationship between
selected variables (age; sex; BMI; race; marital
status; educational level; regular coffee use;
regular black tea use; regular green tea use;Mayo Clin Proc Inn Qual Out n July 2017;1(1):37-48 n http://dx.do
www.mcpiqojournal.orgmean arterial pressure; serum levels of albumin,
creatinine, bilirubin, alanine aminotransferase,
and aspartate aminotransferase; hemoglobin
level; white blood cell count; platelet count; and
the risk scores [MELD, ABIC, mDF, and CP])
and mortality for patients with AH, with risk
estimates reported as hazard ratios (HRs). All
the variables (except for the risk scores) were
screened for entry using a cutoff value of P<.20
in univariate models. The risk scores were
analyzed separately using time-dependent
receiver operating characteristic (ROC) curve
analysis (see below). The AIC27 was subse-
quently used to examine relativemodel fit for all
possible models built using main effects of
variables identified in the first stage. The model
with minimum AIC was selected as the best
model.
Comparing Various Risk Scores for Pre-
dicting Mortality in AH. Next, time-
dependent ROC curve analysis28 was applied
separately for MELD, mDF, ABIC, and CP
scores to determine optimal cutoff values for
predicting mortality among AH cases at the
30-day, 90-day, 180-day, and 1-year intervals,
with area under the curve (AUC) values and
95% CIs presented for all scores and intervals.
A bootstrap resampling procedure29 was used
to estimate standard errors and compare time-
dependent AUCs by risk score, with 1000
samples drawn. The Lille score and Glasgow
alcoholic hepatitis score were not assessed
because blood urea nitrogen level (included in
the Glasgow calculation) was not measured
and bilirubin level at day 7 (included in Lille
score calculation) was measured only for a
small percentage of study participants.
For each risk score, the optimal baseline
cutoff score for predicting 90-day mortality
was determined by minimizing the distance
on the respective ROC curves and perfect per-
formance, ie, 100% sensitivity and 100% spec-
ificity. These cutoff points were then used to
stratify the sample of AH cases and plot
group-specific Kaplan-Meier survival curves
during the 1-year study follow-up with associ-
ated CIs at the 30-day, 90-day, 180-day, and
1-year intervals.
RESULTS
From June 18, 2013, through December 1,
2015, 164 participants with AH and 131i.org/10.1016/j.mayocpiqo.2017.04.004 39
295 Patients enrolled
35 Off study
• 6 Patients withdrew consent
• 29 Deaths
• 74 Completed
• 55 Missed visit
• 59 Completed
• 44 Missed visit
• 3 Patients withdrew consent
• 7 Deaths
• 16 Lost to follow-up
• 7 Patients withdrew consent
• 1 Death
• 25 Lost to follow-up
• 1 Patient detained on house arrest
• 1 Patient incarcerated
4 Off study
• 3 Patients withdrew consent
• 1 Patient incarcerated
103 With 12-mo follow-up expected
• 56 Completed
• 35 Missed visit
91 With 12-mo follow-up expected
129 With 6-mo follow-up expected
• 63 Completed
• 64 Missed visit
127 With 6-mo follow-up expected
26 Off study
36 Off study
164 Baseline expected
• 163 Completed
• 0 In window
• 1 Missed visit
• 131 Completed
• 0 In window
• 0 Missed visit
131 Baseline expected
Cases enrolled Controls enrolled
FIGURE 1. Consort diagram describing the cohort experience through 12-month follow-up. Completed indicates completed the visit
(regardless of whether completed inside or outside the 3-month window); in window, individual still in window but not completed
(3-9 months for the 6-month visit, 9-15 months for the 12-month visit); not yet in window, follow-up time less than 3 months for the
6-month visit and less than 9 months for the 12-month visit; missing visit, past the window/missed the visit.
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40heavy-drinking controls were recruited
(Figure 1). Liver biopsy was performed on 41
patients to exclude concurrent liver disease,
such as autoimmune, hemochromatosis, or
Wilson disease. Thirty-four patients completed
liver biopsy during initial enrollment, and the
remaining 7 patients completed liver biopsy
during follow-up. The median duration of
follow-up for all the participants was 324 days
(range, 1-365 days). The median duration of
follow-up was 281 days (interquartile range
[IQR]¼93-365 days) in patients with AH andMayo Clin Proc Inn Qual Out n July 2017352 days (IQR¼290-365 days) in the control
group. Selected clinical characteristics and lab-
oratory values of cases and controls are shown
in Table 1. There were no differences in age,
sex, BMI, educational level, marital status, black
tea use, or green tea use between cases and con-
trols. However, regular coffee use was signifi-
cantly less frequent in patients with AH than
in heavy-drinking controls (20% vs 44%;
P<.001) (Table 1). Sixty-six patients received
prednisone and 27 received pentoxifylline in
the case group.;1(1):37-48 n http://dx.doi.org/10.1016/j.mayocpiqo.2017.04.004
www.mcpiqojournal.org
TABLE 1. Selected Clinical and Laboratory Characteristics of Patients With Alcoholic Hepatitis and Heavy-Drinking Controlsa,b,c
Characteristic Cases (n¼164) Controls (n¼131) Univariable P value
Age (y) 46.810.9 44.412.5 .08
Male sex (No. [%]) 99 (60.4) 84 (64.1) .50
White race (No. [%]) 144 (87.8) 108 (82.4) .20
BMI 29.17.4 28.77.4 .60
Prednisone use (No. [%]) 66 (40.2) 3 (2.3) NA
Pentoxifylline use (No. [%]) 27 (16.5) 1 (0.7) NA
Regular coffee use (No. [%]) 33 (20.1) 58 (44.3) <.001
Black tea use (No. [%]) 21 (12.8) 18 (13.7) .80
Green tea use (No. [%]) 7 (4.3) 5 (3.8) .80
Educational level (No. [%]) n¼160 n¼130 .08
Low 26 (16.3) 10 (7.7)
Medium 93 (58.1) 84 (64.6)
High 41 (25.6 ) 36 (27.7)
Married (%) 31.1 31.3 >.99
WBC count (x103/mm3) 11,4008300 72002700 <.001
MCV (fl) 10110 92.55.7 <.001
Hemoglobin (f/dL) 0.100.019 0.130.02 <.001
Platelets (103/mm3) 14,5008850 24,4007250 <.001
AST (U/L) 141.590.8 279.0 <.001
ALT (U/L) 64.366.9 25.610.4 <.001
Alkaline phosphatase (U/L) 195.0141.8 75.132.5 <.001
Total bilirubin (mg/dL) 13.511.7 0.50.3 <.001
Albumin (g/dL) 2.00.7 3.90.6 <.001
INR 1.80.5 1.00.3 <.001
Creatinine (mg/dL) 1.00.8 0.80.3 .07
MELD score 22.17.1 7.22.2 <.001
ABIC score 7.51.5 5.61.3 <.001
Child-Pugh score 9.51.7 5.40.6 <.001
mDF score 41.629.1 6.411.0 <.001
aABIC ¼ age, bilirubin, international normalized ratio, and creatinine; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body mass index; INR ¼
international normalized ratio; MCV ¼ mean corpuscular volume; mDF ¼ Maddrey Discriminant Function; MELD ¼ Model for End-Stage Liver Disease; NA ¼ not
applicable; WBC ¼ white blood cell.
bSI conversion factors: To convert WBC count values to 109/L, multiply by 0.001; to convert hemoglobin values to g/L, multiply by 10.0; to convert platelet count values
to 109/L, multiply by 1.0; to convert AST values to mkat/L, multiply by 0.0167; to convert ALT values to mkat/L, multiply by 0.0167; to convert alkaline phosphatase values
to mkat/L, multiply by 0.0167; to convert total bilirubin values to mmol/L, multiply by 17.104; to convert albumin values to g/L, multiply by 10.0; to convert creatinine values
to mmol/L, multiply by 88.4.
cValues are mean  SD unless presented otherwise.
ALCOHOLIC HEPATITISFactors Independently Associated with AH
Based on the model selection algorithm
described in the “Participants and Methods”
section, the best-fitting logistic regression
model for baseline AH status included coffee
consumption, age, and educational level
(low, medium, and high). In summary, regular
coffee consumption was found to be indepen-
dently associated with a significantly lower
risk of AH (OR¼0.26; 95% CI, 0.15-0.46)
(Table 2). Compared with individuals with
low educational level, individuals with me-
dium educational level (OR¼0.38; 95% CI,
0.16-0.89) were less likely to present with
AH at baseline. Increasing age was alsoMayo Clin Proc Inn Qual Out n July 2017;1(1):37-48 n http://dx.do
www.mcpiqojournal.orgpositively associated with AH (OR¼1.03;
95% CI, 1.01-1.06) (Table 2).
Predictors of Mortality in AH
During follow-up, 36 patients with AH died,
with most deaths occurring within the first 6
months after enrollment (Figure 2). The me-
dian time to death was 45 days (IQR¼20-120
days). The estimated 30-day, 90-day, 180-
day, and 1-year survival in patients with AH
were 0.91 (95% CI, 0.87-0.96), 0.85 (95%
CI, 0.80-0.91), 0.80 (95% CI, 0.74-0.87), and
0.75 (95% CI, 0.68-0.83), respectively. The
most common cause of death in the case group
was organ failure (24 of 36), followed by severei.org/10.1016/j.mayocpiqo.2017.04.004 41
TABLE 2. Results of Multivariable Logistic Regression Analysis of Variables Associated With Alcoholic
Hepatitisa
Variable Estimate Standard error c2 P value Odds ratio (95% CI)
Age 0.0327 0.0114 8.2837 .004 1.03 (1.01-1.06)
Educational level
Medium vs low 0.9637 0.4342 4.9257 .03 0.38 (0.16-0.89)
High vs low 0.7445 0.4760 2.4460 .12 0.48 (0.19-1.21)
Regular coffee consumption 1.3424 0.2933 20.9498 <.001 0.26 (0.15-0.46)
aThe following variables were eligible for inclusion in the final model selected by the Akaike Information Criterion: age, educational level,
and coffee consumption.
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42infection (5 of 36). Seven patients died of an
unknown cause. Among controls, mortality
was observed in only 1 individual (heroin
overdose).
The results of univariable and multivari-
able analyses of variables associated with mor-
tality in patients with AH are shown in
Table 3. Although pentoxifylline use at base-
line was a significant univariate predictor of
mortality among AH cases, the association
was in the opposite direction as expected.
The reason for this contradictory finding is
that those given pentoxifylline at baseline
had more severe AH than those not given pen-
toxifylline, as indicated by an average baseline300200100
Time (d)
curve for survival of 164 patients with alcoholic
sents mean survival; dotted lines, 95% CI.
Mayo Clin Proc Inn Qual Out n July 2017MELD score of 27.89 in the pentoxifylline
group vs 20.89 in the nonpentoxifylline group
at baseline. For this reason, we chose to focus
on liver function and other factors besides
treatment to select the final survival model.
The final model selected via the algorithm
described in the Participants and Methods
contained effects for bilirubin, hemoglobin,
platelet count, and albumin. Higher serum
bilirubin level (HR¼1.059; 95% CI, 1.022-
1.089), lower hemoglobin level (HR¼1.263;
95% CI, 1.012-1.575), and lower platelet
count (HR¼1.006; 95% CI, 1.001-1.012)
were found to be independently associated
with increased mortality rates in AH.
Risk Scores and Mortality in AH
Time-dependent ROC curve analysis
(Figure 3) applied separately to each risk score
revealed that CP score had the highest esti-
mated discrimination for predicting mortality
at the 30-day (AUC¼0.77; 95% CI, 0.64-
0.89) and 1-year (AUC¼0.70; 95% CI, 0.6-
0.8) intervals. At the 90-day interval, MELD
(AUC¼0.73; 95% CI, 0.64-0.82) and mDF
(AUC¼0.73; 95% CI, 0.65-0.82) scores were
tied for highest estimated discrimination for
predicting mortality. At the 180-day interval,
mDF (0.71; 95% CI, 0.62-0.81) and ABIC
(AUC¼0.71; 95% CI, 0.61-0.81) scores were
tied for highest estimated discrimination for
predicting mortality. All 30-day AUCs were
greater than 0.70, reflecting fair to good
discriminative power over this interval for all
risk scores. The AUCs for all risk scores were
greater than or very near 0.70 for predicting
90- and 180-day mortality, reflecting fair per-
formance over those intervals. The only risk
score with an AUC near 0.7 at 1 year was
CP score; however, for all risk scores, 30-
and 90-day discrimination performance was;1(1):37-48 n http://dx.doi.org/10.1016/j.mayocpiqo.2017.04.004
www.mcpiqojournal.org
TABLE 3. Univariable and Multivariable Analysis of Variables Associated With
Mortality in Alcoholic Hepatitisa,b
Parameter Univariable P value
Multivariable analysis
P value Hazard ratio (95% CI)
Age .7
Male sex .6
BMI .1
Race .9
Marital status: yes .3
Educational level
Medium vs low .6
High vs low .46
Heavy drinking .8
Regular coffee consumption .99
Regular black tea consumption .7
Regular green tea consumption .6
Mean blood pressure .7
Albumin (1-U decrease) .1 .14 1.587 (0.859-2.933)
Creatinine .4
Bilirubin .049 .001 1.059 (1.022-1.089)
ALT .1
AST .8
Hemoglobin (1-U decrease) .1 .04 1.263 (1.012-1.575)
WBC count .5
Platelet count (1-U decrease) .08 .02 1.006 (1.001-1.012)
aALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body mass index;
WBC ¼ white blood cell.
bThe following variables were eligible for inclusion in the final model selected by the Akaike In-
formation Criterion: albumin, bilirubin, ALT, hemoglobin, platelet count, and BMI.
ALCOHOLIC HEPATITISat the fair level or higher (AUC0.7). Boot-
strap CIs (not presented) were calculated for
each pairwise AUC difference and showed
that there was insufficient statistical evidence
to conclude that the markers differed in their
discrimination performance.
The 90-day ROC curve for each risk score
was used to calculate optimal cutoff values for
predicting survival in this cohort (Table 4).
The 90-day AUCs for MELD, mDF, ABIC,
and CP scores were 0.76, 0.75, 0.73, and
0.77, respectively. The time-dependent ROC
curves at the 90-day interval led to selecting
a cutoff score of 22 or greater for MELD,
44.62 or greater for mDF, 7.603 or greater
for ABIC, and 9 or greater for CP scores.
The Kaplan-Meier survival curves for these
classifications are presented in Figure 4, along
with tick marks on the y-axis that denote
survival probabilities at the 30-day, 90-day,
180-day, and 1-year intervals as well as
associated CIs.
DISCUSSION
Alcoholic hepatitis is a form of alcoholic liver
disease associated with high morbidity and
mortality rates in severe cases. Little is known
about the natural history of AH, risk factors,
and predictors of mortality and recidivism,
especially when patients are defined using
the new consensus definition of AH.24 To bet-
ter characterize the progression of disease, we
prospectively observed heavy drinkers with
and without a clinical diagnosis of AH over a
1-year period. Through this study we were
able to prospectively validate the utility of
MELD and other prognostic scores in predict-
ing short- and long-term mortality associated
with AH. Furthermore, we were able to eluci-
date the relationship between coffee consump-
tion and AH.
There are several population-based and
retrospective studies reporting the association
between coffee consumption and a lower inci-
dence of liver disease.20-23 We found an asso-
ciation between regular coffee consumption
and the presence of AH at baseline, an effect
that persisted after controlling for other fac-
tors. This effect was denoted by a statistically
significant reduction in the odds of AH for
participants who regularly consumed coffee
in the logistic regression model. In fact, heavy
drinkers with regular coffee consumptionMayo Clin Proc Inn Qual Out n July 2017;1(1):37-48 n http://dx.do
www.mcpiqojournal.orgwere 4 times less likely to present with AH.
The mechanism behind this protection is
incompletely understood, although findings
from rodent models suggest favorable alter-
ations in the liver biochemical signaling path-
ways associated with coffee consumption.30
However, note that this finding does not indi-
cate evidence for causation, only an associa-
tion. Because we found coffee to be
associated with a decreased prevalence of
AH in heavy drinkers, we hypothesized that
coffee consumption would also provide mor-
tality benefit in this population. However,
we did not find an association between coffee
consumption and mortality. These data sug-
gest that regular coffee consumption might
provide some benefit in reducing the likeli-
hood of AH in heavy drinkers but does not
confer survival benefit once AH has devel-
oped. Further studies might elucidate whether
coffee consumption in heavy drinkers is hep-
atoprotective, as well as the mechanisms
involved.i.org/10.1016/j.mayocpiqo.2017.04.004 43
TABLE 4. Estimated Survival and 95% CIs for MELD, mDF, ABIC, and CP Scores Based on Optimal Cutoff Scores
Cutoff score
Survival (95% CI)
30 d 90 d 180 d 1 y
MELD
22 0.84 (0.77-0.93) 0.74 (0.65-0.84) 0.67 (0.58-0.78) 0.66 (0.56-0.77)
<22 0.99 (0.96-1) 0.97 (0.94-1) 0.94 (0.89-0.99) 0.86 (0.77-0.96)
mDF
44.62 0.84 (0.76-0.93) 0.73 (0.63-0.85) 0.65 (0.54-0.78) 0.63 (0.52-0.76)
<44.62 0.97 (0.93-1) 0.94 (0.90-0.99) 0.92 (0.86-0.98) 0.84 (0.76-0.94)
ABIC
7.603 0.83 (0.74-0.92) 0.74 (0.64-0.85) 0.65 (0.55-0.78) 0.64 (0.53-0.76)
<7.603 0.98 (0.95-1) 0.94 (0.89-0.99) 0.91 (0.85-0.98) 0.84 (0.76-0.94)
CP
9 0.88 (0.82-0.94) 0.82 (0.75-0.89) 0.75 (0.68-0.84) 0.69 (0.61-0.79)
<9 1 (1-1) 0.95 (0.88-1) 0.92 (0.83-1) 0.92 (0.83-1)
ABIC ¼ age, serum bilirubin, international normalized ratio, and serum creatinine; CP ¼ Child-Pugh; mDF ¼ Maddrey Discriminant
Function; MELD ¼ Model for End-Stage Liver Disease.
MAYO CLINIC PROCEEDINGS: INNOVATIONS, QUALITY & OUTCOMES
44There are several different prognostic
scores used to drive management decisions in
AH, such as CP, mDF, ABIC, and MELD
scores. For each of these prognostic scores,
mortality was extremely unlikely for individ-
uals whose baseline score fell below the corre-
sponding cutoff point (survival >97% and
>94% at 30 and 90 days, respectively). How-
ever, the scores were less precise in deter-
mining which patients above these cutoff
scores were at risk for mortality in terms of
the mortality rate being lower than expected
for individuals presenting scores higher than
the cutoff scores at baseline, reflected by the
12% to 17% range of 1-month mortality rates.
This inaccuracy may reflect the importance of
recidivism in increasing mortality risk. Mortal-
ity prediction may improve if a validated recid-
ivism risk score is added to the current models.
A drawback of the CP and mDF scores, which
are used in patients with alcoholic cirrhosis
and AH, is the lack of standardization of the
prothrombin time from laboratory to labora-
tory. Thus, both CP and mDF scores may
vary depending on the sensitivity of the reagent
used to measure the prothrombin time. This
variability has been rectified by expressing
the prothrombin time as international normal-
ized ratio taking into consideration the sensi-
tivity of the thromboplastin reagent used for
the test by the individual laboratory. Moreover,
the CP score includes ascites and hepatic en-
cephalopathy, which are subjective parameters
and can depend on the experience of theMayo Clin Proc Inn Qual Out n July 2017observer assessing the variable. Also, ABIC
score has been criticized because the group
characterized as low risk (ABIC score <6.71)
exhibited approximately 17% mortality at 84
days.25 Both MELD and CP are generic scores
that have been validated across a variety of liver
diseases. Moreover, the MELD score is used to
prioritize organ allocation for liver transplant
in the United States and in other countries.
Alcoholic hepatitisespecific scores such as
the mDF and the ABIC would be attractive
only if they were clearly superior to the generic
scores. This was not the case in the present
study. Finally, the CP score has not been
extensively validated in AH. Therefore, we
chose to focus on the MELD score further as
described later herein.
Despite retrospective studies supporting its
utility, prospective validation and optimiza-
tion of the ideal cutoff point for pharmacologic
therapy are not available.13 The MELD score
was previously validated using a retrospective
study, with a score 21 or greater reported to
have 75% sensitivity and 75% specificity in
predicting 90-day mortality.11 In a prospective
study, we confirmed the MELD score to be a
strong independent factor that predicts mor-
tality in AH. More specifically, we found a
baseline MELD score of 22 or greater to be
the optimal score that predicts the largest dif-
ference in mortality over the year-long period
of follow-up. Although the optimal cutoff
score in this study was slightly different from
that previously observed (22 vs 21), this
;1(1):37-48 n http://dx.doi.org/10.1016/j.mayocpiqo.2017.04.004
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FIGURE 3. Receiver operating characteristic (ROC) curves for Model for End-Stage Liver Disease (MELD); Maddrey Discriminant
Function (mDF); age, serum bilirubin, international normalized ratio, and serum creatinine (ABIC); and Child-Pugh (CP) scores for
predicting 30-day, 90-day, 180-day, and 1-year mortality rates. A, The ROC curve for MELD scores. The area under the curve (AUC)
for 30-day mortality is 0.76 (95% CI, 0.67-0.85); 90-day mortality, 0.73 (95% CI, 0.64-0.82); 180-day mortality, 0.69 (95% CI, 0.58-
0.79); and 1-year mortality, 0.62 (95% CI, 0.51-0.73). B, The ROC curve for mDF scores. The AUC for 30-day mortality is 0.75 (95%
CI, 0.67-0.84); 90-day mortality, 0.73 (95% CI, 0.65-0.82); 180-day mortality, 0.71 (95% CI, 0.62-0.81); and 1-year mortality, 0.65
(95% CI, 0.55-0.76). C, The ROC curve for ABIC scores. The AUC for 30-day mortality is 0.73 (95% CI, 0.59-0.87); 90-day mortality,
0.71 (95% CI, 0.6-0.82); 180-day mortality, 0.71 (95% CI, 0.61-0.81); and 1-year mortality, 0.64 (95% CI, 0.53-0.76). D, The ROC
curve for CP scores. The AUC for 30-day mortality is 0.77 (95% CI, 0.64-0.89), 90-day mortality, 0.69 (95% CI, 0.56-0.83); 180-day
mortality, 0.7 (95% CI, 0.58-0.81); and 1-year mortality, 0.7 (95% CI, 0.6-0.8).
ALCOHOLIC HEPATITISstudy provides substantial evidence for the
MELD score as a reliable predictor of mortality
in AH. The previously accepted mDF cutoff
point of greater than 32 could not be vali-
dated. Instead, we identified 44.62 as theMayo Clin Proc Inn Qual Out n July 2017;1(1):37-48 n http://dx.do
www.mcpiqojournal.orgoptimal mDF cutoff score, a value discordant
from the previously reported limit of 32. As
discussed later herein, this finding may be
attributed to the overall reduced mortality
rate observed in the present sample. Thesei.org/10.1016/j.mayocpiqo.2017.04.004 45
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FIGURE 4. Kaplan-Meier survival curves for 4 risk stratification models stratified by optimal cutoff points (90-day interval). A, Model
for End-Stage Liver Disease (MELD) score (<22 vs 22). B, Maddrey Discriminant Function (mDF) score (<44.62 vs 44.62). C,
Age, serum bilirubin, international normalized ratio, and serum creatinine (ABIC) score (<7.603 vs 7.603). D, Child-Pugh (CP) score
(<9 vs 9).
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46findings further validate the utility of the
MELD score for predicting the short- and
long-term mortality associated with AH. We
believe that a MELD score of 22 or greater
can be used as a clinical tool to prognosticate
patients with AH, to guide treatment decisions
in the acute setting, and to stratify patients in
investigational protocols.
The strengths and weakness of this study
merit further discussion. The major strength
is the prospective multicenter nature of theMayo Clin Proc Inn Qual Out n July 2017study, with close follow-up at tertiary care
hepatology centers. The major limitation is
the lack of information available on comorbid
medical conditions that can affect outcomes,
such as infection, gastrointestinal bleeding,
or renal failure. This may contribute to the dif-
ference in baseline information and outcome
compared with the Steroids or Pentoxifylline
for Alcoholic Hepatitis (STOPAH) trial. In
addition, information regarding addiction
treatment, medication adherence, and relapse;1(1):37-48 n http://dx.doi.org/10.1016/j.mayocpiqo.2017.04.004
www.mcpiqojournal.org
ALCOHOLIC HEPATITISinformation (besides at 6- and 12-month in-
tervals) in the case and control groups is also
lacking. This limitation makes it difficult to
ascertain the contributions of inadequate treat-
ment, noncompliance, and relapse to risk of
mortality. Furthermore, because most (28 of
36) observed deaths in the AH case group
occurred before 6 months, relapse information
is of limited use in predicting mortality in this
study. Future studies should collect more
frequent relapse information to aid in assess-
ing the relative contribution of relapse to mor-
tality in AH cases. We recommend the use of
telephone interviews, if possible, to reduce
study costs and logistical issues. The lack of
close follow-up during the first 6 months of
the study is a related weakness. The median
of all observed death times was 105 days, indi-
cating that a 6-month follow-up visit schedule
may be too infrequent to fully capture the rela-
tionship between risk scores and risk of mor-
tality in the short-term. Future studies
should follow patients more closely during
the first 6 months to provide information
regarding factors associated with mortality
and recidivism. The study inclusion criteria
for the AH case group, specifically, total bili-
rubin level greater than 2 mg/dL (to convert
to mmol/L, multiply by 17.104) and aspartate
aminotransferase level greater than 50 U/L
(to convert to mkat/L, multiply by 0.0167)
may also be viewed as limitations because
they include mild AH as well as severe AH.
However, the authors note that these criteria
are similar to guidance provided in a recent
commentary article in the journal Gastroenter-
ology and coincide with our colleagues’
recently published work from this cohort.24,25
The mortality rate of the present study is lower
and worth discussing. The difference in mor-
tality rates between this study and the STO-
PAH trial likely represents a difference in
patient selection between the 2 studies. The
STOPAH trial selected patients with severe
AH, which is reflected by the higher mean 
SD mDF score (62.627.2 vs 41.629.1),
and the present study enrolled a wider range
of severity, including mild AH. Finally, the
relatively small numbers of patients and large
proportion of white individuals in the present
study make it difficult to explain the relation-
ship between race, educational level, and risk
of AH.Mayo Clin Proc Inn Qual Out n July 2017;1(1):37-48 n http://dx.do
www.mcpiqojournal.orgCONCLUSION
We found that patients with AHhave high short-
and long-term mortality rates, with most deaths
(85.7%) occurring within 6 months after enroll-
ment. Regular coffee consumption was associ-
ated with lower odds of development of AH in
heavy drinkers but did not provide mortality
benefit once AH developed. Alcoholic hepatitis
with a MELD score of 22 or greater was associ-
ated with higher 30-day, 90-day, 180-day, and
1-yearmortality rates. This study provides a pro-
spective assessment of a variety of important
issues in AH and concurrently uncovers several
new issues that warrant future study.ACKNOWLEDGMENTS
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